Fate Therapeutics, Inc.

DB:F6T Stock Report

Market Cap: €167.4m

Fate Therapeutics Valuation

Is F6T undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of F6T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate F6T's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate F6T's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for F6T?

Key metric: As F6T is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for F6T. This is calculated by dividing F6T's market cap by their current revenue.
What is F6T's PS Ratio?
PS Ratio13x
SalesUS$13.45m
Market CapUS$174.26m

Price to Sales Ratio vs Peers

How does F6T's PS Ratio compare to its peers?

The above table shows the PS ratio for F6T vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.5x
HPHA Heidelberg Pharma
13x16.6%€110.5m
MDG1 Medigene
3.4x15.2%€25.1m
2INV 2invest
8.9xn/a€68.4m
FYB Formycon
8.7x22.9%€527.9m
F6T Fate Therapeutics
13x23.6%€174.3m

Price-To-Sales vs Peers: F6T is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (8.5x).

Price to Sales Ratio vs Industry

How does F6T's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
F6T 13.0xIndustry Avg. 8.8xNo. of Companies5PS048121620+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: F6T is expensive based on its Price-To-Sales Ratio (13x) compared to the European Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is F6T's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

F6T PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13x
Fair PS Ratio0.001x

Price-To-Sales vs Fair Ratio: F6T is expensive based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst F6T forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.53
€6.32
+312.8%
40.9%€11.47€2.87n/a13
Feb ’26€1.34
€5.99
+347.5%
35.9%€9.50€2.85n/a13
Jan ’26€1.52
€5.99
+293.2%
35.9%€9.50€2.85n/a13
Dec ’25€2.97
€5.95
+100.6%
35.9%€9.44€2.83n/a13
Nov ’25€2.17
€5.77
+166.2%
39.4%€10.73€3.13n/a12
Oct ’25€3.13
€5.77
+84.8%
39.4%€10.73€3.13n/a12
Sep ’25€3.18
€5.77
+81.5%
39.4%€10.73€3.13n/a12
Aug ’25€4.93
€6.32
+28.3%
34.4%€11.18€3.73n/a14
Jul ’25€3.04
€6.32
+108.1%
34.4%€11.18€3.73n/a14
Jun ’25€3.20
€6.12
+91.4%
36.7%€11.06€3.69n/a14
May ’25€3.82
€7.20
+88.9%
25.7%€11.08€4.62n/a15
Apr ’25€6.74
€7.20
+6.8%
25.7%€11.08€4.62n/a15
Mar ’25€6.53
€6.92
+6.0%
33.7%€11.07€1.85n/a14
Feb ’25€5.75
€5.77
+0.4%
50.5%€12.04€1.85€1.3415
Jan ’25€3.58
€5.77
+61.2%
50.5%€12.04€1.85€1.5215
Dec ’24€2.35
€5.71
+142.8%
50.5%€11.92€1.83€2.9715
Nov ’24€1.72
€6.89
+300.2%
46.0%€15.15€3.79€2.1716
Oct ’24€2.05
€6.89
+235.8%
46.0%€15.15€3.79€3.1316
Sep ’24€2.30
€6.44
+179.5%
47.4%€14.67€3.67€3.1817
Aug ’24€3.60
€7.29
+102.6%
40.0%€14.38€3.60€4.9319
Jul ’24€4.37
€7.41
+69.7%
39.4%€14.53€3.63€3.0419
Jun ’24€4.54
€7.41
+63.2%
39.4%€14.53€3.63€3.2019
May ’24€5.51
€7.70
+39.8%
39.6%€14.52€3.63€3.8219
Apr ’24€5.00
€7.67
+53.4%
40.5%€14.75€3.69€6.7420
Mar ’24€5.74
€7.70
+34.2%
40.3%€15.01€3.75€6.5320
Feb ’24€5.62
€7.78
+38.4%
40.1%€14.70€3.68€5.7520
Analyst Price Target
Consensus Narrative from 13 Analysts
€6.62
Fair Value
76.9% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 22:37
End of Day Share Price 2025/02/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fate Therapeutics, Inc. is covered by 32 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research